By Kate Holton, Andrew MacAskill and Elizabeth Piper LONDON, Jan 23 (Reuters) - British finance minister Rachel Reeves will ...

Opioid agonist/antagonist has a big impact in phase IIb trial ...

AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now publicly funded in Ontario and are among the first therapies to receive ...

Earlier this week, Daiichi Sankyo and AstraZeneca received approval in China for ENHERTU as the first HER2-directed antibody-drug conjugate for second-line treatment of HER2 positive metastatic ...

Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...

A U.S. appeals court on Friday reinstated a lawsuit claiming some of the world’s largest drug and medical‑device companies ...

Amendment in NDCTR eases approvals by replacing prior permission with prior intimation: Dr Premnath Shenoy: Nandita Vijayasimha, Bengaluru Saturday, January 24, 2026, 08:00 Hrs [I ...

This symposium took place during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The aim ...

Delays in transferring patients with stroke for advanced treatment are linked to worse disability, fewer lifesaving procedures, and more complications, a large US study shows.

Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...

Japanese pharma Daiichi Sankyo (TSE: 4568) and British partner AstraZeneca (LSE: AZN) said Enhertu (trastuzumab deruxtecan) ...